In the VEHAT-two trial for ITP, 8% of patients receiving a placebo infusion experienced an infusion reaction. This surprising finding underscores the necessity of placebo-controlled studies to differentiate true drug-related adverse events from effects caused by the procedure or patient expectation.
The LUNA-three trial demonstrated that ITP patients on rilzabrutinib showed improved fatigue. Notably, even patients whose platelet counts did not respond to the drug still had better fatigue outcomes than the placebo group, suggesting a separate anti-inflammatory benefit on quality of life.
Yanalumab not only blocks the BAF receptor to prevent B-cell maturation but also acts as a potent B-cell depleter. This two-headed mechanism is why it's named after the two-faced Roman god Janus, providing a memorable link between its name and function.
An oncologist observed that some ITP patients treated with rilzabrutinib or yanalumab experienced an unexpected side benefit: improvement in their seasonal allergy symptoms. This suggests these autoimmune-targeted therapies may have broader effects on immune dysregulation beyond just ITP.
The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.